Literature DB >> 23430804

Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.

Laura López-Marín1, Luis G Gutiérrez-Solana, Luis Aldamiz-Echevarria Azuara, Rogelio Simón de Las Heras, Anna Duat Rodríguez, Verónica Cantarín Extremera.   

Abstract

Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disorder with potentially severe degenerative consequences. Clinical diagnosis is not easy, although biochemical confirmation is straightforward, and sometimes patients are diagnosed at a late age. It is widely believed, for inborn errors of metabolism in general, that early diagnosis and management is of paramount importance for improving the prognosis of the disease. The objective of this study was to identify specific populations at risk of suffering from Hunter syndrome. Urine samples were obtained from children between the ages of 0 to 18, belonging to known risk groups of mucopolysaccharidosis (MPS) type II, for the semi-quantitative (GAG test) and quantitative determination of glycosaminoglycans (GAG). One case of Hunter syndrome was found among the 130 samples that were collected and analysed. This study supports the feasibility of early diagnosis and the usefulness of screening tests for MPS II in specific paediatric populations.

Entities:  

Year:  2013        PMID: 23430804      PMCID: PMC3755579          DOI: 10.1007/8904_2012_204

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  38 in total

1.  Natural progression of neurological disease in mucopolysaccharidosis type II.

Authors:  Joshua B Holt; Michele D Poe; Maria L Escolar
Journal:  Pediatrics       Date:  2011-04-25       Impact factor: 7.124

2.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

3.  Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome).

Authors:  Brian J Wolfe; Sophie Blanchard; Martin Sadilek; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Anal Chem       Date:  2010-12-30       Impact factor: 6.986

4.  Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.

Authors:  A Tylki-Szymanska; A Jurecka; Z Zuber; A Rozdzynska; J Marucha; B Czartoryska
Journal:  Acta Paediatr       Date:  2011-06-29       Impact factor: 2.299

5.  High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Jeong-Yi Kwon; Kiljun Ko; Young Bae Sohn; Su Jin Kim; Sung Won Park; Se-Hwa Kim; Sung-Yoon Cho; Dong-Kyu Jin
Journal:  Am J Med Genet A       Date:  2011-05-12       Impact factor: 2.802

6.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).

Authors:  Y V Voznyi; J L Keulemans; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

Review 7.  Multidisciplinary management of Hunter syndrome.

Authors:  Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith
Journal:  Pediatrics       Date:  2009-11-09       Impact factor: 7.124

Review 8.  Magnetic resonance imaging findings in Hunter syndrome.

Authors:  Chelsea T Finn; Leonardo Vedolin; Ida V Schwartz; Roberto Giugliani; Charlotte A Haws; Andrew P Prescot; Perry F Renshaw
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

9.  [Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry].

Authors:  M del Toro-Riera
Journal:  Rev Neurol       Date:  2007-02-19       Impact factor: 0.870

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  2 in total

1.  Attenuated form of type II mucopolysaccharidoses (Hunter syndrome): pitfalls and potential clues in diagnosis.

Authors:  Partha Pratim Chakraborty; Shinjan Patra; Sugata Narayan Biswas; Himanshu Barman
Journal:  BMJ Case Rep       Date:  2018-02-23

2.  Challenges in the Management of Mucopolysaccharidosis Type II (Hunter's Syndrome) in a Developing Country: a Case Report.

Authors:  Ibraheem Rasheeedah; Oladele Patrick; AbdulAzeez Abdullateef; Abdulkadri Mohammed; Katibi Sherifat; Ibraheem Gbadebo
Journal:  Ethiop J Health Sci       Date:  2015-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.